Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 4/20 | 1.00 |
| ▸ | CISD1 | Q9NZ45 | 4/20 | 1.00 |
| ▸ | GSK3B | P49841 | 3/20 | 1.00 |
| ▸ | PIM1 | P11309 | 3/20 | 1.00 |
| ▸ | PIM3 | Q86V86 | 3/20 | 1.00 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 1.00 |
| ▸ | CDC7 | O00311 | 2/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 2/20 | 1.00 |
| ▸ | DYRK3 | O43781 | 2/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 2/20 | 1.00 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 1.00 |
| ▸ | CSNK1D | P48730 | 2/20 | 1.00 |
| ▸ | CLK2 | P49760 | 2/20 | 1.00 |
| ▸ | GSK3A | P49840 | 2/20 | 1.00 |
| ▸ | NEK4 | P51957 | 2/20 | 1.00 |
| ▸ | CSNK1G2 | P78368 | 2/20 | 1.00 |
| ▸ | CAMK2D | Q13557 | 2/20 | 1.00 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 1.00 |
| ▸ | HIPK4 | Q8NE63 | 2/20 | 1.00 |
| ▸ | BRSK1 | Q8TDC3 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8537237 | 1.00 | DYRK1A (1.00) | DYRK1ACISD1GSK3BPIM1PIM3 | |
| SCHEMBL29374484 | 1.00 | DYRK1A (1.00) | DYRK1ACISD1GSK3BPIM1PIM3 | |
| SCHEMBL2199252 | 1.00 | DYRK1A (1.00) | DYRK1ACISD1GSK3BPIM1PIM3 | |
| SCHEMBL1640032 | 0.90 | DYRK1A (0.81) | DYRK1ACISD1GSK3BPIM1PIM3 | |
| SCHEMBL9248740 | 0.90 | DYRK1A (0.81) | DYRK1ACISD1GSK3BPIM1PIM3 | |
| SCHEMBL1641525 | 0.90 | DYRK1A (0.81) | DYRK1ACISD1GSK3BPIM1PIM3 | |
| SCHEMBL15421279 | 0.88 | PDE4B (1.00) | DYRK1ACISD1GSK3BPIM1PIM3 | |
| SCHEMBL8171885 | 0.88 | PDE4B (1.00) | DYRK1ACISD1GSK3BPIM1PIM3 | |
| SCHEMBL8171882 | 0.88 | PDE4B (1.00) | DYRK1ACISD1GSK3BPIM1PIM3 | |
| SCHEMBL1248758 | 0.88 | PIM1 (1.00) | DYRK1ACISD1GSK3BPIM1PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160102065-A1 | NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREOF | PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) | 2016-04-14 | — | — | US | claimed |
| WO-2005082363-A1 | THIAZOLONE COMPOUNDS FOR TREATMENT OF CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2005-09-09 | — | — | WO | claimed |
| US-12590127-B2 | Split photoactive yellow protein complementation system and uses thereof | PARIS SCIENCES ET LETTRES (FR) | 2026-03-31 | — | — | US | disclosed |
| WO-2024052353-A1 | PROXIMITY INDUCING SYSTEM AND USES THEREOF | SORBONNE UNIVERSITE (FR) | 2024-03-14 | — | — | WO | disclosed |
| US-20220169682-A1 | SPLIT PHOTOACTIVE YELLOW PROTEIN COMPLEMENTATION SYSTEM AND USES THEREOF | PARIS SCIENCES ET LETTRES (FR) | 2022-06-02 | — | — | US | disclosed |
| EP-3947355-A1 | SPLIT PHOTOACTIVE YELLOW PROTEIN COMPLEMENTATION SYSTEM AND USES THEREOF | Paris Sciences et Lettres (FR) | 2022-02-09 | — | — | EP | disclosed |
| US-20210038566-A1 | USE OF MODULATORS OF NEET PROTEINS FOR THE TREATMENT OF INFECTION | ENYO PHARMA (FR) | 2021-02-11 | — | — | US | disclosed |
| WO-2020201538-A1 | SPLIT PHOTOACTIVE YELLOW PROTEIN COMPLEMENTATION SYSTEM AND USES THEREOF | PARIS SCIENCES ET LETTRES – QUARTIER LATIN (FR) | 2020-10-08 | — | — | WO | disclosed |
| EP-3719007-A1 | SPLIT PHOTOACTIVE YELLOW PROTEIN COMPLEMENTATION SYSTEM AND USES THEREOF | Paris Sciences et Lettres - Quartier Latin (FR) | 2020-10-07 | — | — | EP | disclosed |
| US-10501413-B2 | Inhibitors of the Notch transcriptional activation complex and methods for use of the same | UNIVERSITY OF MIAMI (US) | 2019-12-10 | — | — | US | disclosed |
| EP-3164411-B1 | FLUOROGEN ACTIVATING AND SHIFTING TAG (FAST) | PARIS SCIENCES LETTRES QUARTIER LATIN (FR) | 2019-08-28 | — | — | EP | disclosed |
| WO-2005082363-A1 | THIAZOLONE COMPOUNDS FOR TREATMENT OF CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2005-09-09 | — | — | WO | disclosed |
| EP-0915090-A1 | Compounds useful as hypoglycemic agents and for treating Alzheimer's disease | ELI LILLY AND COMPANY (US) | 1999-05-12 | — | — | EP | disclosed |
| US-5731336-A | USING ARYL-SUBSTITUTED RHODAMINES | ELI LILLY AND COMPANY (US) | 1998-03-24 | — | — | US | disclosed |
| US-5716975-A | NONTOXIC RHODANINE DERIVATIVES; ANTIDIABETIC AGENTS, CATHEPSIN D INHIBITORS, B-AMYLOID PROTEIN REDUCTION | ELI LILLY AND COMPANY (US) | 1998-02-10 | — | — | US | disclosed |
| US-5661168-A | ADMINISTERING RHODANINE DERIVATIVES TO CONTROL DIABETES | ELI LILLY AND COMPANY (US) | 1997-08-26 | — | — | US | disclosed |
| WO-1996022772-A1 | METHOD FOR TREATING MULTIPLE SCLEROSIS | ELI LILLY AND COMPANY (US) | 1996-08-01 | — | — | WO | disclosed |
| EP-0722729-A2 | Aryl-substituted rhodanines for treating multiple sclerosis | ELI LILLY AND COMPANY (US) | 1996-07-24 | — | — | EP | disclosed |
| US-5523314-A | RHODANINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1996-06-04 | — | — | US | disclosed |
| EP-0587377-A2 | Thiazolidinone derivatives as hypoglycemic agents and for treating Alzheimer's disease | ELI LILLY AND COMPANY (US) | 1994-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169682-A1 | SPLIT PHOTOACTIVE YELLOW PROTEIN COMPLEMENTATION SYSTEM AND USES THEREOF | BLVRB, IK, HBG2 | DYRK1A 75/4885CISD1 720/4885GSK3B 4812/4885 |
| US-20210038566-A1 | USE OF MODULATORS OF NEET PROTEINS FOR THE TREATMENT OF INFECTION | PEBP1, ELANE, MME | DYRK1A 4753/4885CISD1 2695/4885GSK3B 3449/4885 |
| US-10501413-B2 | Inhibitors of the Notch transcriptional activation complex and methods for use of the same | NOTCH1, CBFB, HES1 | DYRK1A 3661/4885CISD1 511/4885GSK3B 1070/4885 |
| US-20160102065-A1 | NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREOF | PPARG, PPARA, TYR | DYRK1A 3727/4885CISD1 3776/4885GSK3B 3223/4885 |
| US-12590127-B2 | Split photoactive yellow protein complementation system and uses thereof | BLVRB, HBG2, Q6ZSR9 | DYRK1A 151/4885CISD1 758/4885GSK3B 4765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.